Bhatt DL et al. |
Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial. |
2017 |
Clin Cardiol |
pmid:28294373
|
Brinton EA and Mason RP |
Prescription omega-3 fatty acid products containing highly purified eicosapentaenoic acid (EPA). |
2017 |
Lipids Health Dis |
pmid:28137294
|
Mosca L et al. |
Usefulness of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Women to Lower Triglyceride Levels (Results from the MARINE and ANCHOR Trials). |
2017 |
Am. J. Cardiol. |
pmid:27939227
|
Ballantyne CM et al. |
Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies. |
2016 May-Jun |
J Clin Lipidol |
pmid:27206952
|
Gose T et al. |
Prostaglandin transporter (OATP2A1/SLCO2A1) contributes to local disposition of eicosapentaenoic acid-derived PGE3. |
2016 |
Prostaglandins Other Lipid Mediat. |
pmid:26692285
|
Bays HE et al. |
Icosapent ethyl: Eicosapentaenoic acid concentration and triglyceride-lowering effects across clinical studies. |
2016 |
Prostaglandins Other Lipid Mediat. |
pmid:27418543
|
Fialkow J |
Omega-3 Fatty Acid Formulations in Cardiovascular Disease: Dietary Supplements are Not Substitutes for Prescription Products. |
2016 |
Am J Cardiovasc Drugs |
pmid:27138439
|
Ballantyne CM et al. |
Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies. |
2016 |
Atherosclerosis |
pmid:27596132
|
Braeckman RA et al. |
Effect of concomitant icosapent ethyl (eicosapentaenoic acid ethyl ester) on the pharmacokinetics of atorvastatin. |
2015 |
Clin Drug Investig |
pmid:25471740
|
Yamanushi TT et al. |
Oral administration of eicosapentaenoic acid or docosahexaenoic acid modifies cardiac function and ameliorates congestive heart failure in male rats. |
2014 |
J. Nutr. |
pmid:24523492
|